Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

peptide linker conjugate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (7) Drug-Linker Conjugates for ADC (18) Peptide-Drug Conjugates (PDCs) (4) Antibody-Drug Conjugates (ADCs) (3) CXCR (1) Drug Derivative (1) EGFR (3) Fluorescent Dye (1) GCGR (2) Isotope-Labeled Compounds (2) LDLR (1) Liposome (1) Microtubule/Tubulin (3) MMP (1) Topoisomerase (2) TRP Channel (1)
By Research Areas:	Cancer (33) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (1)
Click Chemistry:	BCN (1)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) ADC Linker Target Protein Ligand-Linker Conjugates PROTAC-Linker Conjugates for PAC Drug-Linker Conjugates for ADC RXFP Receptor E3 Ligase Ligand-Linker Conjugates CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19813A

mDPR-Val-Cit-PAB-MMAE TFA	Drug-Linker Conjugates for ADC	Cancer
mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition ^{[1] ^.}

HY-43869

Vipivotide tetraxetan Ligand-Linker Conjugate PSMA-617 Ligand-linker conjugate	ADC Linker	Cancer
Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) .

HY-13631E

Deruxtecan Maximum Cited Publications 17 Publications Verification MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-P10736A

AMG133 peptide payload TFA	GCGR	Metabolic Disease
AMG133 peptide payload TFA is the TFA salt form of AMG133 peptide payload (HY-P10736). AMG133 peptide payload TFA is a GLP-1 agonist that can be used for synthesis of AMG133 (HY-164535) as a peptide linker conjugate .

HY-147021

MC-Val-D-Cit-PAB-PNP	ADC Linker	Cancer
MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.

HY-P10736

AMG133 peptide payload	GCGR	Metabolic Disease
AMG133 peptide payload is a GLP-1 agonist that can be used as a peptide linker conjugate of AMG133 (HY-164535) .

HY-128941

CCK2R Ligand-Linker Conjugates 1	Drug-Linker Conjugates for ADC	Cancer
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker .

HY-129360

Ala-Ala-Asn-PAB	ADC Linker	Cancer
Ala-Ala-Asn-PAB is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .

HY-129360A

Ala-Ala-Asn-PAB TFA	ADC Linker	Cancer
Ala-Ala-Asn-PAB TFA is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .

HY-158199

BCN-HS-PEG2-bis(PNP)	ADC Linker	Cancer
BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .

HY-100566

SuO-Val-Cit-PAB-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
SuO-Val-Cit-PAB-MMAE is a *agent-linker* conjugate for ADC** by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .

HY-101909

Val-Cit-PAB-MMAF	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAF is a *agent-linker* conjugate for ADC*. Val-Cit-PAB-MMAF contains the ADCs linker* (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)

HY-44177

Val-Cit-PAB-MMAF sodium	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAF sodium is a *agent-linker* conjugate for ADC*. Val-Cit-PAB-MMAF sodium contains the ADCs linker* (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)

HY-147239

MC-VA-PABC-MMAE	Drug-Linker Conjugates for ADC	Cancer
MC-VA-PABC-MMAE is a *agent-linker* conjugate for ADC*. MC-VA-PABC-MMAE contains the ADCs linker* (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-169322

APL-1081 Mal-Exo-EVC-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
APL-1081 (Mal-Exo-EVC-MMAE) is part of an antibody-conjugated active molecule (ADC). APL-1081 is conjugated with an ADC linker (peptide Mal-Exo-EEVC) and a potent tubulin polymerization inhibitor, MMAE (HY-15162) .

HY-150241

DOPE-NHS	Liposome	Others
DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .

HY-153395

PH-HG-005-5	Drug-Linker Conjugates for ADC	Cancer
PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis .

HY-100374

Val-Cit-PAB-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-147286

Ac-Lys-Val-Cit-PABC-MMAE	Drug-Linker Conjugates for ADC	Cancer
Ac-Lys-Val-Cit-PABC-MMAE is a *agent-linker* conjugate for ADC*. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker* (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-P10742

CBX-12	Peptide-Drug Conjugates (PDCs) Topoisomerase	Cancer
CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631) .

HY-13631ES4

Deruxtecan-d5 MC-GGFG-DXD-d₅	Isotope-Labeled Compounds Drug-Linker Conjugates for ADC	Cancer
Deruxtecan-d₅ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES

Deruxtecan-d4 MC-GGFG-DXD-d₄	Drug-Linker Conjugates for ADC Isotope-Labeled Compounds	Others
Deruxtecan-d₄ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-147286A

Ac-Lys-Val-Cit-PABC-MMAE formic	Drug-Linker Conjugates for ADC	Cancer
Ac-Lys-Val-Cit-PABC-MMAE (formic) is a *agent-linker* conjugate for ADC*. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker* (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor Monomethyl auristatin E (HY-15162) .

HY-147270

MC-VA-PAB-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-VA-PAB-Exatecan is a *agent-linker* conjugate for ADC*. MC-VA-PAB-Exatecan contains the ADC linker* (peptide MC-VA-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-VA-PAB-Exatecan synthesized ADC shows good antitumor activity .

HY-P99881

Rolinsatamab talirine ABBV 176	Drug-Linker Conjugates for ADC	Cancer
Rolinsatamab talirine (ABBV 176) is an *antibody-drug conjugate* (ADC) targeting prolactin receptor (PRLR)*. Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide* linker, and SGD-1882 (HY-101127) .

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease Cancer
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-100374G

Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-W071967

Alloc-Val-Ala-pAB	ADC Linker	Cancer
Alloc-Val-Ala-PAB is a peptide cleavable linker used in the synthesis of antibody-drug conjugates (ADCs). The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.

HY-145663

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM	Drug-Linker Conjugates for ADC	Cancer
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety .

HY-P4095

NoxaBH3	CXCR	Cancer
NoxaBH3 is a cysteine-based cross-linked peptide with increased cell permeability and higher inhibitory activity against Mcl-1. NoxaBH3 binds to the endogenous CXCR4 ligand to produce ubiquitin-Noxabh3 conjugate. NoxaBH3 is then delivered to cancer cells .

HY-W729138

Fmoc-D-homoArg(Et)2-OH hydrochloride	ADC Linker	Others
Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .

HY-P10775

BT1769	Peptide-Drug Conjugates (PDCs) MMP	Cancer
BT1769 is a MT1-MMP-targeted (K_D = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .

HY-P10740

CBP-1018	Peptide-Drug Conjugates (PDCs) TRP Channel	Cancer
CBP-1018 is a PDC (peptide drug conjugate) consisting of a dual targeting FRα/TRPV6 ligand (blue part) coupled to Monomethyl auristatin E (HY-15162) (red part) via a linker (HY-78738) (black part). CBP-1018 is expected to be used in breast cancer research .

HY-164165

Paclitaxel-2′-succinate NHS ester	Microtubule/Tubulin Drug Derivative	Cancer
Paclitaxel-2′-succinate NHS ester is a paclitaxel derivative with a succinic acid linker, in which the carboxyl group is activated by the NHS ester. The NHS ester group is highly reactive toward amino or hydroxyl groups and can be used to conjugate with other molecules such as peptides, proteins, antibodies, enzymes or polymers. Paclitaxel-2′-succinate NHS ester can be used in the development of nanomedicines and in the study of cancer therapy .

HY-P4073

ANG1005 GRN1005; Paclitaxel trevatide	Peptide-Drug Conjugates (PDCs) LDLR	Cancer
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .

HY-138298A

Trastuzumab deruxtecan 1 Publications Verification DS-8201; DS-8201a	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (DS-8201a) is an anti-*human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate* (ADC)*. Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker*, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-164992

Trastuzumab MMAE	Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin	Cancer
Trastuzumab MMAE is an anti-human *epidermal growth factor receptor 2 (HER2) antibody-drug conjugate* (ADC)*. Trastuzumab MMAE is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker* Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab MMAE can be used for the research of HER2-positive breast cancer .

HY-138298

Trastuzumab deruxtecan (solution) 1 Publications Verification DS-8201 (solution); DS-8201a (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-*human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate* (ADC)*. Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker*, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

Cat. No.	Product Name	Type

HY-100374G

Val-Cit-PAB-MMAE (GMP)	Fluorescent Dye
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

Cat. No.	Product Name	Type

HY-163551

BNP peptide/KLH	Biochemical Assay Reagents
The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

BNP peptide/KLH

Biochemical Assay Reagents

The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-150241

DOPE-NHS	Drug Delivery
DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .

HY-100374G

Val-Cit-PAB-MMAE (GMP)	Biochemical Assay Reagents
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

Cat. No.	Product Name	Target	Research Area

HY-P10736A

AMG133 peptide payload TFA	GCGR	Metabolic Disease
AMG133 peptide payload TFA is the TFA salt form of AMG133 peptide payload (HY-P10736). AMG133 peptide payload TFA is a GLP-1 agonist that can be used for synthesis of AMG133 (HY-164535) as a peptide linker conjugate .

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease Cancer
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P4073

ANG1005 GRN1005; Paclitaxel trevatide	Peptide-Drug Conjugates (PDCs) LDLR	Cancer
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .

HY-P10736

AMG133 peptide payload	GCGR	Metabolic Disease
AMG133 peptide payload is a GLP-1 agonist that can be used as a peptide linker conjugate of AMG133 (HY-164535) .

HY-P10742

CBX-12	Peptide-Drug Conjugates (PDCs) Topoisomerase	Cancer
CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631) .

HY-P4095

NoxaBH3	CXCR	Cancer
NoxaBH3 is a cysteine-based cross-linked peptide with increased cell permeability and higher inhibitory activity against Mcl-1. NoxaBH3 binds to the endogenous CXCR4 ligand to produce ubiquitin-Noxabh3 conjugate. NoxaBH3 is then delivered to cancer cells .

HY-W729138

Fmoc-D-homoArg(Et)2-OH hydrochloride	ADC Linker	Others
Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .

HY-P10775

BT1769	Peptide-Drug Conjugates (PDCs) MMP	Cancer
BT1769 is a MT1-MMP-targeted (K_D = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .

HY-P10740

CBP-1018	Peptide-Drug Conjugates (PDCs) TRP Channel	Cancer
CBP-1018 is a PDC (peptide drug conjugate) consisting of a dual targeting FRα/TRPV6 ligand (blue part) coupled to Monomethyl auristatin E (HY-15162) (red part) via a linker (HY-78738) (black part). CBP-1018 is expected to be used in breast cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P99881

Rolinsatamab talirine ABBV 176	Drug-Linker Conjugates for ADC	Cancer
Rolinsatamab talirine (ABBV 176) is an *antibody-drug conjugate* (ADC) targeting prolactin receptor (PRLR)*. Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide* linker, and SGD-1882 (HY-101127) .

Cat. No.	Product Name	Chemical Structure

HY-13631ES4

Deruxtecan-d5
Deruxtecan-d₅ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES

Deruxtecan-d4
Deruxtecan-d₄ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

Cat. No.	Product Name		Classification

HY-158199

BCN-HS-PEG2-bis(PNP)		BCN
BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .

Cat. No.	Product Name		Classification

HY-150241

DOPE-NHS		Phospholipids
DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: